Introducing the Dexcom G6® Continuous Glucose Monitoring (CGM) System

Indicated for use in diabetes treatment decisions for adult and pediatric patients ages 2 years and older with type 1 or type 2 diabetes.

Greater Glucose Awareness

The Dexcom CGM system delivers up to 288 readings every 24 hours, empowering patients by providing continuous data and feedback. On average, Dexcom CGM users check their screen 29 times per day.1

Informed Diabetes Management Decisions

CGM users adjust their insulin more frequently, and CGM rate of change (ROC) arrows were the dominant factor in insulin dose adjustment.2

Exceptional Accuracy

No fingersticks needed for calibration, treatment decisions and insulin dosing.*

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

rt-CGM Use Reduces A1C for Patients on Both Insulin Pump and Injection Therapy3

Professional Society Guidelines

Consensus statements from endocrine leaders point to the many benefits of continuous glucose monitoring in many patient populations.4-6

CGM Is a "Gold Standard"

In its recently published Clinical Practice Guidelines, the Endocrine Society calls out CGM as a “gold standard” of diabetes care for type 1 patients.5

CGM Lowers A1C

Used in conjunction with intensive insulin therapy, CGM can be useful in helping lower A1C in diabetes patients. Recommended for adult type 1 diabetes patients (≥18 years old).4

More Patients Should Use CGM

The AACE calls for wider use of CGM in diabetes treatment, because it improves outcomes by reducing hypoglycemia. They go on to recommend CGM be used in all patients with severe hypoglycemia.7

1

Dexcom internal data on file, 2016.

2

Pettus J, Edelman S. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technology & Therapeutics, Volume 18, Supplement 2, 2016.

3

Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.

4

American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):SS5-S64 

5

Peters AL, Ahmann AJ, Battelino T, et al. Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2016:jc.2016-2534.

6

Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocr Pract. 2016;22(2):231-261.

7

Fonseca V, Grunberger G, Anhalt H et al. CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016;22(8):1008-1021.